Prelude Therapeutics (PRLD) grants CMO 450,000 stock options at $4.70

Rhea-AI Filing Summary

Prelude Therapeutics Inc reported that Chief Medical Officer Charles Q. Morris received an employee stock option grant covering 450,000 shares of common stock at an exercise price of $4.70 per share.

The option vests 25% on May 1, 2027, then 1/48 of the total shares monthly until fully vested, contingent on continued service. The option expires on April 30, 2036, and all 450,000 options are reported as held directly following this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Morris Charles Q

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	450,000	$4.70	$2.12M

Holdings After Transaction: Employee Stock Option (right to buy) — 450,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 450,000 shares Exercise price: $4.70 per share Post-grant derivative holdings: 450,000 options +2 more

5 metrics

Option grant size 450,000 shares Employee stock option underlying common stock

Exercise price $4.70 per share Employee stock option strike price

Post-grant derivative holdings 450,000 options Total options held following this grant

Initial vesting date May 1, 2027 25% of total option shares vest

Expiration date April 30, 2036 Stock option expiration

Key Terms

Employee Stock Option (right to buy), exercise price, vesting, expiration date

4 terms

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

exercise price financial

"conversion_or_exercise_price of $4.7000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The stock option vests as to 25% of the total shares on May 1, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date set to April 30, 2036 for the option"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morris Charles Q

(Last) (First) (Middle)

C/O PRELUDE THERAPEUTICS INCORPORATED

175 INNOVATION BOULEVARD

(Street)

WILMINGTON DELAWARE 19805

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Prelude Therapeutics Inc [ PRLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$4.7	05/01/2026		A		450,000		(1)	04/30/2036	Common Stock	450,000	$4.7	450,000	D

Explanation of Responses:

1. The stock option vests as to 25% of the total shares on May 1, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Bryant D. Lim, Attorney-in-Fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Prelude Therapeutics (PRLD) disclose in this Form 4 filing?

Prelude Therapeutics disclosed that Chief Medical Officer Charles Q. Morris received an employee stock option grant for 450,000 shares at a $4.70 exercise price. The filing records this as a compensation-related acquisition, with all granted options held directly after the transaction.

How many Prelude Therapeutics stock options were granted to the CMO?

The Chief Medical Officer received an employee stock option grant covering 450,000 underlying shares of common stock. These options give the right to buy Prelude Therapeutics shares at a fixed $4.70 exercise price, subject to the specific vesting schedule and continued service conditions described in the filing.

What is the exercise price of the new Prelude Therapeutics stock options?

The newly granted employee stock options have an exercise price of $4.70 per share. This means the holder can purchase Prelude Therapeutics common stock at $4.70 once the options vest, provided the options have not expired or been forfeited under the grant’s terms.

When do the Chief Medical Officer’s Prelude Therapeutics options vest?

The options vest 25% of the total shares on May 1, 2027, then 1/48 of the total shares monthly until fully vested. Vesting is contingent on the reporting person continuing to provide service to Prelude Therapeutics on each applicable vesting date, as described in the footnote.

When do the newly granted Prelude Therapeutics stock options expire?

The employee stock options granted to the Chief Medical Officer expire on April 30, 2036. After that expiration date, any unexercised options become worthless, so the holder must exercise vested options before that date if they choose to use them.

Is the Form 4 transaction a market purchase or a compensation grant at Prelude Therapeutics?

The Form 4 records a compensation-related grant, not a market purchase. The transaction is coded as an acquisition of derivative securities (employee stock options) awarded to the Chief Medical Officer, reflecting a grant or award rather than an open-market buy or sell of existing shares.